AbstractmRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage, short durability of protection, and lack of access in low-resource regions. We have developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine against SARS-CoV-2 that is stable at room temperature. This saRNA vaccine is formulated with a nanostructured lipid carrier (NLC), providing stability, ease of manufacturing, and protection against degradation. In preclinical studies, this saRNA/NLC vaccine induced strong humoral immunity, as demonstrated by high pseudovirus neutralization titers to the Alpha, Beta, and Delta variants of concern and induction of bone marrow-resident antibody-secreting cells. Robust Th1-biased T-cell responses were also observed after prime or homologous prime-boost in mice. Notably, the saRNA/NLC platform demonstrated thermostability when stored lyophilized at room temperature for at least 6 months and at refrigerated temperatures for at least 10 months. Taken together, this saRNA delivered by NLC represents a potential improvement in RNA technology that could allow wider access to RNA vaccines for the current COVID-19 and future pandemics.
While mRNA vaccines have been highly effective over the past 2 years in combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), waning of vaccine-induced antibody responses and lack of induction of respiratory tract immunity contribute to ongoing infection and transmission. However, intranasally (i.n.) administered vaccines may induce mucosal immunity at the site of respiratory virus infection and may thus boost protection. In this work, we present an i.n. administered SARS-CoV-2 self-amplifying RNA (saRNA) vaccine, delivered by a nanostructured lipid carrier (NLC), which induces both potent respiratory mucosal and systemic immune responses. Following prime-boost immunization in C57BL/6 mice, i.n. vaccination induces serum neutralizing antibody titers, bone marrow resident IgG-secreting cells, and robust systemic polyfunctional T cells, similar to intramuscular (i.m.) vaccination. The intranasal vaccine additionally induces key SARS-CoV-2-reactive lung-resident polyfunctional memory and lung-homing T cell populations. As a booster following i.m. administration, the i.n. vaccine also elicits robust mucosal and systemic immunity, exceeding an i.m. booster, durable for at least 4 months. The potent mucosal and systemic immunogenicity of this i.n. saRNA vaccine may be key for combating SARS-CoV-2 and other respiratory pathogens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.